Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26613779 | 1.00 | HRH1 (0.32) | HRH1HTR6RXFP1DHFRSMN1; SMN2 | |
| SCHEMBL22377821 | 0.96 | RXFP1 (0.34) | RXFP1DHFRSMN1; SMN2HIF1AGRIN1 | |
| SCHEMBL22379751 | 0.95 | DHFR (0.33) | HRH1HTR6DHFRSMN1; SMN2HIF1A | |
| SCHEMBL26613805 | 0.95 | DHFR (0.33) | HRH1HTR6DHFRSMN1; SMN2HIF1A | |
| SCHEMBL21599506 | 0.95 | HRH1 (0.33) | HRH1HTR6RXFP1SMN1; SMN2HIF1A | |
| SCHEMBL21599502 | 0.95 | HRH1 (0.33) | HRH1HTR6RXFP1SMN1; SMN2HIF1A | |
| SCHEMBL22378172 | 0.94 | HRH1 (0.32) | HRH1HTR6RXFP1 | |
| SCHEMBL22378331 | 0.93 | KDM4E (0.34) | HRH1HTR6DHFRSMN1; SMN2HIF1A | |
| SCHEMBL22378412 | 0.93 | KDM4E (0.34) | HRH1HTR6DHFRSMN1; SMN2HIF1A | |
| SCHEMBL22379108 | 0.93 | KDM4E (0.34) | HRH1HTR6DHFRSMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11800797-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-10-24 | — | — | US | disclosed |
| US-11800797-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-10-24 | — | — | US | disclosed |
| US-20200274074-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200274074-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CYP1A1, CRY2 | HRH1 835/4885HTR6 2325/4885RXFP1 3137/4885 |
| US-11800797-B2 | Heterocyclic compound and organic light-emitting device including the same | CRY1, CYP1A1, CRY2 | HRH1 835/4885HTR6 2325/4885RXFP1 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.